Drug Trial Radar · NCT05156710
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Jun 9, 2022
Primary completion
Oct 21, 2025
Study completion Oct 20, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: * Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR * Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: * To assess the overall efficacy of BIVV020 in prevention or treatment of AMR * To characterize the safety and tolerability of BIVV020 in kidney transplant participants * To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants * To evaluate the immunogenicity of BIVV020
Conditions
- Transplant Rejection
Interventions
BIVV020 (SAR445088)Drug
Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Intravenous immunoglobulin (IVIg)Drug
Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Rituximab or biosimilarDrug
Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Antithymocyte globulin (ATG)Drug
Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
TacrolimusDrug
Pharmaceutical Form: Tablet Route of Administration: Oral
MycophenolateDrug
Pharmaceutical Form: Tablet Route of Administration: Oral
CorticosteroidsDrug
Pharmaceutical Form: Vary Route of Administration: Vary
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Treatment failure rateTime frame: Up to Week 49
- Cohort B: AMR resolution rateTime frame: Up to Week 49
Locations
27 sites in 7 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center- Site Number : 8400100
Los Angeles, California
University of California Los Angeles Medical Center- Site Number : 8400103
Los Angeles, California
University of California San Francisco - Parnassus Heights- Site Number : 8400001
San Francisco, California
Massachusetts General Hospital- Site Number : 8400007
Boston, Massachusetts
Brigham & Women's Hospital- Site Number : 8400004
Boston, Massachusetts
NYU Langone Medical Center- Site Number : 8400102
New York, New York
University of Wisconsin Hospitals and Clinics- Site Number : 8400003
Madison, Wisconsin
Investigational Site Number : 1240101
Vancouver, British Columbia, Canada
Investigational Site Number : 1240001
Vancouver, British Columbia, Canada
Investigational Site Number : 1240002
London, Ontario, Canada
Investigational Site Number : 1240003
Montreal, Quebec, Canada
Investigational Site Number : 2500007
Bordeaux, France
Investigational Site Number : 2500002
Créteil, France
Investigational Site Number : 2500001
Paris, France
Investigational Site Number : 2500005
Toulouse, France
Investigational Site Number : 2760002
Berlin, Germany
Investigational Site Number : 2760004
Essen, Germany
Investigational Site Number : 2760001
Munich, Germany
Investigational Site Number : 3800004
Bologna, Emilia-Romagna, Italy
Investigational Site Number : 3800002
Rome, Lazio, Italy
Investigational Site Number : 3800001
Brescia, Lombardy, Italy
Investigational Site Number : 3800003
Milan, Milano, Italy
Investigational Site Number : 7240004
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240003
Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7240002
Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7520001
Huddinge, Sweden
Investigational Site Number : 7520002
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.